Xilio TherapeuticsXLO
13F holders, Q4 2025 (December 31)At the end of Q4 2025, 37 institutions reported holding Xilio Therapeutics Inc. (XLO) in their 13F filings, up 1 from Q3 2025. 10 opened new positions and 9 sold out. The largest holders were Gilead Sciences, Inc. ($5.8M), Bain Capital Life Sciences Investors, LLC ($4.7M) and Frazier Life Sciences Management, L.P. ($3.8M). 3 famous investors held it, including Steve Cohen (0.0% of Point72 Asset Management's portfolio), Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Xilio Therapeutics Inc.
- CUSIP
- 98422T100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $10.3M |
| Exits | 9 | $751K |
All 13F filers, Q3 2025 → Q4 2025: 19,090,660 shares bought and 1,122,680 shares sold, net +17,967,980 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 37 holders
| Gilead Sciences, Inc. | 0.30% | No change | 9,105,451 | $5.8M |
| Bain Capital Life Sciences Investors, LLC | 0.36% | Add +61.4% | 7,372,686 | $4.7M |
| Frazier Life Sciences Management, L.P. | 0.10% | New | 5,915,091 | $3.8M |
| Point72 Asset Management | 0.00% | New | 4,000,000 | $2.6M |
| Sio Capital Management, LLC | 0.23% | New | 2,134,537 | $1.4M |
| Stempoint Capital LP | 0.22% | New | 2,030,028 | $1.3M |
| Merck & Co., Inc. | 0.34% | No change | 1,483,758 | $950K |
| Vanguard Group Inc. | 0.00% | No change | 1,255,692 | $804K |
| Empery Asset Management, LP | 0.67% | — | 1,183,040 | $757K |
| Ghisallo Capital Management LLC | 0.03% | New | 1,113,222 | $713K |
| Morgan Stanley | 0.00% | Reduce -12.7% | 839,850 | $538K |
| AJU IB Investment Co., Ltd. | 1.88% | No change | 667,742 | $427K |
| FMR LLC | 0.00% | No change | 511,820 | $328K |
| Citadel Advisors | 0.00% | New | 436,216 | $279K |
| Renaissance Technologies | 0.00% | Add +68.3% | 344,416 | $220K |
| Geode Capital Management, LLC | 0.00% | No change | 328,972 | $211K |
| State Street Corp. | 0.00% | Add +13.7% | 186,390 | $119K |
| Velan Capital Investment Management LP | 0.06% | New | 170,000 | $109K |
| Gsa Capital Partners LLP | 0.01% | New | 147,966 | $95K |
| Stonepine Capital Management, LLC | 0.06% | New | 126,270 | $81K |
| Northern Trust Corp. | 0.00% | No change | 66,609 | $43K |
| Two Sigma Investments, LP | 0.00% | Reduce -29.3% | 62,032 | $40K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 56,081 | $36K |
| Jane Street Group, LLC | 0.00% | New | 42,080 | $27K |
| HRT Financial LP | 0.00% | Add +28.9% | 31,886 | $20K |
| Mariner, LLC | 0.00% | No change | 25,000 | $16K |
| LPL Financial LLC | 0.00% | Reduce -32.3% | 21,000 | $13K |
| Raymond James Financial Inc. | 0.00% | No change | 18,761 | $12K |
| XTX Topco Ltd | 0.00% | Reduce -77.3% | 17,304 | $11K |
| Dunhill Financial, LLC | 0.00% | No change | 10,274 | $7K |
| Investors Asset Management of Georgia Inc. /Ga/ | 0.00% | No change | 10,000 | $6K |
| Pinnacle Financial Group, LLC / IL | 0.00% | No change | 10,000 | $6K |
| BlackRock, Inc. | 0.00% | No change | 2,037 | $1K |
| Key Financial Inc | 0.00% | No change | 830 | $531 |
| Private Wealth Management Group, LLC | 0.00% | No change | 310 | $199 |
| Bank of America Corp. | 0.00% | Add +6.1% | 261 | $167 |
| UBS Group AG | 0.00% | Reduce -98.5% | 203 | $130 |
"% of holder's portfolio" is XLO's weight in each manager's 13F, not the share of Xilio Therapeutics Inc. the manager owns.